Abingworth closes new $356 million fund for life sciences

30 October 2023
lab_biotech_research_pipettes_big

UK-based investor Abingworth has raised $356 million for a new fund focused on clinical co-development in the life sciences.

A transatlantic firm with offices in Massachusetts and California as well as London, Abingworth is part of the global investment group Carlyle (Nasdaq: CG).

The final closing sum for its Clinical Co-Development Co-Investment Fund came in well over the target of $300 million, with the company now having raised over $930 million since 2021 for late-stage clinical programs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology